Efficacy of Focal Lasers in Central Serous Chorioretinopathy by Arthi, M
Dissertation on 
EFFICACY OF FOCAL LASERS IN CENTRAL SEROUS 
CHORIORETINOPATHY 
Submitted in partial fulfillment of requirements of 
M.S. OPHTHALMOLOGY 
BRANCH - III 
 
REGIONAL INSTITUTE OF OPHTHALMOLOGY 
MADRAS MEDICAL COLLEGE 
CHENNAI- 600 003 
 
THE TAMILNADU 
DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
 APRIL 2017 
           CERTIFICATE 
This is to certify that this dissertation entitled “EFFICACY OF 
FOCAL LASERS IN CENTRAL SEROUS 
CHORIORETINOPATHY” is a bonafide record of the research work 
done by Dr. ARTHI. M, post graduate in Regional Institute of 
Ophthalmology and Government Ophthalmic Hospital, Madras Medical 
College and Government General Hospital, Chennai-03, in partial 
fulfillment of the regulations laid down by The Tamil Nadu Dr. M.G.R. 
Medical University for the award of M.S. Ophthalmology Branch III, 
under my guidance and supervision during the academic years 2014-
2017. 
 
Dr. M. RAJAKUMARI MS.,DO.     
 Chief – Uvea and Retina Services                                                     
RIO – GOH                                                                     
Egmore, Chennai – 08 
DR. WAHEEDA NAZIR MS., 
DO.,
Director and Superintendent 
RIO – GOH 
Egmore, Chennai - 08 
 
 
 
 
 
 
 
   Dr. M. K. MURALIDHARAN M.S.,Mch., 
   Dean, 
   Madras Medical College. 
   and Government General Hospital 
   Chennai – 03 
 
 
 
ACKNOWLEDGEMENT 
I  express  my  sincere  thanks  and  gratitude  to Prof. 
Dr.M.K.Muralidharan, MS., Mch., Dean, Madras Medical College 
and Government General Hospital for permitting me to conduct this 
study.  
  
I have great pleasure in thanking Prof. Dr. WAHEEDA NAZIR M.S., 
DO., Director and Superintendent, Regional Institute of Ophthalmology 
– Government Ophthalmic Hospital, Madras Medical College, for her 
valuable advice in preparing this dissertation.  
I express my profound gratitude to Prof. Dr. M. RAJAKUMARI M.S., 
DO., my unit chief and my guide for her valuable guidance and constant 
support at every stage throughout the period of this study.  
I am very grateful to my unit assistants Dr. K. RAVIKUMAR M.S., 
Dr. M. PERYANAYAGI M.S., and Dr. A. NANDHINI D.A., M.S., 
for rendering their valuable advice and guidance for the study.  
I wish to express my sincere thanks to all the professors, assistant 
professors and all my colleagues who had helped me in bringing out this 
study.  
Finally, I am indebted to all the patients for their sincere co-operation 
for the completion of this study 
  
  
  
 
DECLARATION BY THE CANDIDATE 
I hereby declare that this dissertation entitled “ EFFICACY OF 
FOCAL LASERS IN CENTRAL SEROUS 
CHORIORETINOPATHY” is a bonafide and genuine research work 
carried out by me under the guidance of Prof. Dr. M. Rajakumari M.S., 
D.O., 
 
 
DATE: 
PLACE:       DR. ARTHI.M  
 
 
 
 
 
CONTENTS 
Sr.  
NO 
TITLE 
PAGE  
NO 
 PART -  I   
1 INTRODUCTION 3 
2 ANATOMY OF THE RETINA AND MACULA 5 
3 EPIDEMIOLOGY 10 
4 RISK FACTORS 11 
5 
6 
7 
8 
9 
10 
PATHOGENESIS 
CLINICAL FEATURES   
INVESTIGATIONS                                                       
DIFFERENTIAL DIAGNOSIS                                 
NATURAL COURSE AND OUTCOME                
TREATMENT                                                          
13 
15 
19 
27 
30 
31 
   
 PART – II   
11 AIMS AND OBJECTIVES 37 
12 MATERIALS AND METHODS  38 
13 RESULTS  41 
14 DISCUSSION  69 
15 
16 
CONCLUSION  
FUTURE PROSPECTS                                                          
74 
75 
   
 PART – III  
 BIBLIOGRAPHY   
 PROFORMA  
KEY TO MASTERCHART 
MASTERCHART 
 
   
 
 
 
 
 
 
 
  
 
 
 
 
 
PART   I 
 
 
 
 
 
 
 
 
 
 
  
ABBREVIATIONS 
CSR  - Central Serous Chorioretinopathy 
PED  - Pigment Epithelial Detachment  
FFA  - Fundus Fluorescein Angiography 
OCT  - Optical Coherence tomography 
ICG  - Indocyanine Green Angiography 
BCVA  - Best Corrected Visual Acuity 
CNVM - Choroidal neovascular membrane 
RPE  - Retinal Pigment Epithelium 
FAZ  - Foveal Avascular Zone 
 
          
 
 
 
 
 
INTRODUCTION 
Central Serous chorioretinopathy (CSR) is an idiopathic disorder 
characterized by a localized and circumscribed serous detachment of the 
sensory retina at the macula secondary to leakage from the 
choriocapillaris through single or multiple hyperpermeable Retinal 
Pigment Epithelium (RPE) sites. It is usually confined to the central 
macula. 
CSR has a long history of changing names reflective of the previous 
uncertainty about the etiology of the pathological process. 
Albrecht von Graefe
1
 1866 first described it as a recurrent central 
retinitis. 
Horniker
2
 1922 agreed that the pathology was localized to the retina but 
thought these patients had an underlying angioneurosis causing 
angiospasm and exudation. He used the name capillarospastic central 
retinitis.  
Gifford and Marquardt
3
 shared Horniker’s view and coined the term 
central angiospastic retinopathy.  
Bennet
4
 also localized the disease to the retina and applied the name 
central serous retinopathy. 
Through fluorescein angiography, Maumenee
5
 changed the concept of 
the primary tissue affected by describing the leak occurring at the level 
of the RPE.  
Based on fundus flourescein angiographic findings, Gass
6
 added on to 
this view and termed the condition idiopathic central serous 
choroidopathy. 
 Today CSR is the preferred term, since we understand that the 
neurosensory detachment occurs due to a leak in RPE resulting from the 
hyperpermeability at the choroid. 
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ANATOMY OF THE RETINA AND 
MACULA 
The retina, which is the inner nervous layer of the eyeball, is a thin, 
delicate and transparent membrane. The surface area of the retina is 
266mm 
2.
Its thickness in the posterior pole in the peripapillary region is 
0.56 mm as compared to its thickness in the ora serrata where it is 0.1 
mm. It has a purplish red hue in living subjects which becomes opaque 
after death.  
The retina is has strong attachments to the margins of the optic disc and 
at the ora serrata.   
EMBRYOLOGY 
The retina is derived from neuroectoderm, where the Retinal Pigment 
Epithelium and neurosensory retina are derived from the outer and inner 
layers of the optic cup, respectively.  
THE MACULA 
The macula lutea, is the area for the most distinct vision is at the centre 
of the posterior part of the retina. It is a yellowish oval area which 
measures about 5 mm in diameter and lies about 3 mm to the lateral side 
of the optic disc. The yellow carotenoid pigment, xanthophylls cause the 
macula to appear yellow in colour. The fovea centralis is the central 
depressed area in the canter of the macula lutea .It measures about 1.85 
mm in diameter. It corresponds to central 5 
o 
of the visual field and is the 
most sensitive part of the retina. The foveola, which is 0.35 mm in 
diameter, forms the central floor of the fovea. A tiny depression in the 
centre of the foveola is the umbo which corresponds to the foveal light 
reflex. There are no blood vessels in the fovea which comprises the 
foveal avascular zone which is normally around 500 micrometer in 
diameter. 
THE OPTIC DISC 
The optic disc lies about 3 mm medially to the macula lutea. It is pale 
pink and measures about 1.5 mm in diameter. The edge of the disc is 
slightly raised, while the central part has a slight depression, through 
which the central retinal vessels enter and leave the eye. It is at the optic 
disc that the optic nerve fibers exit the eye by piercing the sclera at the 
lamina cribrosa. Posterior to the optic disc, the nerve fibers are 
myelinated, whereas anterior to the disc they are nonmyelinated. At the 
optic disc, there is a complete absence of rods and cones; thus, it is 
insensitive to light and is referred to as the blind spot. 
ORA SERRATA 
The ora serrata is the scalloped anterior margin of the retina where the 
nervous tissues of the retina ends. The anterior part of the retina is 
nonreceptive and extends forward from the ora serrata over the ciliary 
body to the posterior surface of the iris. 
 
 
 
 
 
RETINAL PIGMENT EPITHELIUM 
This layer consists of a single layer of cells that extends forward from 
the margin of the optic nerve to the ora serrata anteriorly. The cells are 
narrow and tall in the posterior polar region and become flattened near 
the ora serrata. The cells are hexagonal in a tangential section. The basal 
end of each cell is much infolded and rests on a basement membrane, 
forming a part of Bruch's membrane of the choroid. The apical ends of 
the cell show multiple microvilli which are embedded in 
glycosaminoglycans and act as an adhesive binding the pigment layer to 
the neural layer. The adjacent cell membranes are bound together in the 
basal region by the zonula adherens, which encircles the cell, and in the 
apical region by the zonula occludens, which also surrounds the cell and 
practically obliterates the intercellular space. These tight junctions form 
the outer blood retinal barrier. The Inner blood retinal barrier is formed 
by the zonaoccludens of the endothelial cells of the retinal capillaries 
bound together. 
The RPE plays a pivotal role in photoreceptor renewal, maintaining the 
blood retinal barrier and transport of nutrients through the blood retinal 
barrier. 
 
 
 
 
 
BLOOD SUPPLY 
The blood supply of the retina is from two sources.  
1) The outer laminae, including the rods and cones and outer nuclear 
layer, are supplied by the choroidal capillaries. 
2) The inner laminae are supplied by the central artery and vein.  
The retinal arteries are anatomic end arteries, and there are no 
arteriovenous anastomoses. Small twigs from the superior and inferior 
divisions of the central retinal artery supply the macula. Cilioretinal 
artery is present in 20% of the individuals, which is a branch from the 
ciliary circulation .  
MICROSCOPIC ANATOMY 
Based on light microscopic findings, the whole retina was said to be 
composed of 10 layers. These are, from outside inward, as follows: 
1. The pigment epithelium 
2. The rods and cones  
3. The external limiting membrane  
4. The outer nuclear layer  
5. The outer plexiform layer  
6. The inner nuclear layer 
7. The inner plexiform layer 
8. The ganglion cells 
9. The nerve fiber layer 
10. The internal limiting membrane 
At the fovea, the fibres of the outer plexiform layer run obliquely 
forming the Henle’s layer. The fovea contains 10% of the cone 
population of the retina. The foveola contains only the cones and their 
nuclei and remaining layer of the retina are absent
7
. 
        FIGURE 1 – ANATOMY OF THE RETINA AND MACULA  
 
 
 
 
 
 
EPIDEMIOLOGY 
The age- and sex-adjusted incidence of CSR in a recent population-
based study was found to be 5–6 per 100 000 people8.  
CSR has a tendency to occur in middle aged individuals between the age 
group of 20 – 50 years. The mean age by two large retrospective case 
control studies was reported to be 51
9, 10
 though older studies reported a 
mean age considerably lesser than this. CSR is not known to occur in 
children and prepubertal individuals with only two case report of CSR in 
children till date
11, 12
. 
 In terms of gender, there is a male predilection with the reported male: 
female ratio 3:1
9,10
.  
Race also plays a role in CSR, with more caucasians, Hispanics, and 
Asians affected and relatively uncommon in African Americans
13
.   
CSR has been found to be associated with hypermetropic or emmetropic 
patients in western countries but such an association has not been found 
in asian countries which has a high prevalence of myopes. 
 
 
 
 
 
 
RISK FACTORS FOR CENTRAL SEROUS 
CHORIORETINOPATHY 
Many risk factors have been identified by various investigators for CSR. 
 Individuals with type A personality and mental stress are 
implicated as strong risk factors in CSR. Patients with CSR 
commonly give history of multiple stressful events in their life. 
This was first emphasized by Yannuzzi
14
 
 
in his study based on 
the the Jenkins Activity Survey, which showed that CSR was 
more common in individuals with type A personality as compared 
to controls. Werry and Arends
15
 using the Minnesota Multiphasic 
Personality Inventory Test, showed that CSR patients are more 
likely to show hypochondria or hysteria and have a conversional 
neurosis.  
 Endogenous and exogenous hypercortisolism have been 
implicated in CSR by multiple researchers. Tittl et al
10
, found that 
corticosteroids are risk factors in addition to psychotropic 
medications and hypertension. Inhaled, intranasal, intramuscular, 
and topical dermatological corticosteroids have also been 
implicated in CSR pathogenesis. Endogenous corticosteroids are 
also thought to contribute to the pathogenesis of disease.  
 Other risk factors, implicated by a study by Haimovici16 et al, 
included  
 antibiotics,  
 pregnancy,  
 untreated hypertension,  
 allergic respiratory disease and  
 alcohol.  
 The association of CSR with pregnancy was also reported by 
Gass
17
. Recent studies by Liu and collegues also implicated 
Helicobacter pylori infection and sleep disturbances and in 
individuals with sleep disturbances.
18 
The study also confirmed 
the association of other risk factors listed above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATHOGENESIS OF CENTRAL SEROUS 
CHORIORETINOPATHY 
The pathology in CSR consists of separation of the neurosensory retina 
from the RPE at the macula due to the accumulation of subretinal fluid 
between these layers.  
Patients with CSR may have subretinal deposits of four forms fibrin, 
lipid, macrophages, and outer photoreceptor segments. Subretinal lipid 
is usually found in chronic CSC in older patients and appears as 
discrete, hardedged, subretinal accumulations typically at the borders of 
a neurosensory detachment. CNVM is a more common disorder causing 
accumulation of lipid in the subretinal space. 
Multiple theories for CSR were put forward and refuted with emerging 
clinical evidence in the past. The current theory for pathophysiology is 
based on the demonstration of multiple leaks in case of active CSR and 
the resolution of the subretinal fluid once the leaks subsided. Normally 
there is a balance between the tissue oncotic pressure and hydrostatic 
pressure causes the normal flow of the fluid from the retina to the 
choroid 
19
. The various risk factors listed above lead to the rise in the 
levels of circulating epinephrine and norepinephrine which increases the 
hydrostatic pressure. This causes a hyperpermeability in the choroidal 
vasculature which further leads to pigment epithelial detachment and 
disruption of the RPE which cause the accumulation of the fluid 
between the neurosensory retina and the pigmented layer. This is 
supported by evidence from indocyanine green angiography which 
shows that the RPE defects overly the areas of choroidal vascular 
hyperpermeability 
20
. 
HISTOPATHOLOGY 
There exists only limited histopathologic information on CSC. 
Neurosensory detachment with subretinal fibrin deposition has been 
reported. Yoshioka and Katsume31 described a focal area of 
degenerated RPE with adjacent damaged choriocapillaris endothelial 
cells in animal models. These endothelial abnormalities were sealed by 
platelet-fibrin clots. OCT provides optical biopsies in which retinal 
atrophy has been visualised. Patients with a history of long standing 
CSR may develop cystic spaces within the retina which gives rise to 
cystoid macular degeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL FEATURES 
SYMPTOMS 
Common symptoms of CSR are diminution of vision associated with 
various distortions including micropsia, metamorphopsia, scotomas, and 
chromatopsia. The visual acuity is usually mildly reduced to around 6/9 
to 6/12 but can be worse than 6/60 in severe or recurrent disease. The 
visual acuity may be improvable with hyperopic correction. CSR 
usually tends to be unilateral in younger and bilateral in older patients. 
SIGNS 
CSR can present in three different ways:  
 classic acute chorioretinopathy, 
 chronic diffuse retinal pigment epitheliopathy (DRPE), and 
 bullous retinal detachment.  
Classic or acute CSR, the most common form, consists of a well 
circumscribed neurosensory detachment at the macula, which may vary 
in shape from round to oval, elevates the macula and resulting in the 
neutralisation of the normal foveal reflex. This collection of clear fluid 
has a characteristic halo formed by light reflexes which leads to the 
formation of a ring reflex. The detachment may be of variable size. 
Retinal Pigment Epithelial Detachments (PEDs) of the serous type are 
also commonly seen in association with CSR. On biomicroscopy, a PED 
appears as a wellcircumscribed, orange-colored elevation with a slightly 
darker rim that can illuminate with a slit beam aimed from the side. 
When the RPE separates from the underlying Bruch’s membrane it leads 
to a pigment Epithelial Detachment. These detachments are often less 
than 0.25 disk diameter, but can be larger. Some patients may have the 
deposition of subretinal fibrin. 
Chronic Diffuse Retinal Pigment Epitheliopathy the subretinal fluid 
which is longstanding causes decompensation of the RPE which leads to 
an altered pigmentation. Patients with Diffuse Retinal Pigment 
Epitheliopathy generally have a more pronounced and irreversible loss 
of vision. Examination of the retina with a +90D lens may show 
thinning and cystoids changes. The associated RPE changes can be any 
one of the following. 
 The RPE atrophy characterised by hypopigmentation and 
increased visibility of the underlying larger choroidal vessels. 
 Focal hyperpigmentation of the RPE.  
 RPE hyperplasia which manifests as bone spicules.  
Within the detachment, the subretinal fluid may be clear, or with 
subretinal deposits. This may be suggestive of CNVM.  
The rare, form of CSR that causes bullous retinal detachments has 
numerous exuberant leaks, multiple PEDs, and bullous retinal 
detachments. This condition is frequently bilateral. These detachments 
are associated with shifting subretinal fluid and subretinal fibrinous 
exudates. This has been reported in great number in Japan and among 
organ transplant patients. Patients with bullous detachment have a large 
number and increased size of choroidal hyperpermeability areas in ICG 
angiography. Bilaterality is the norm (84%). While some of the patients 
initially presented with bullous changes, others converted from classic 
CSC (36%). Those patients who experienced visual loss greater than 
20/40 had macular damage. 
 FIGURE 2 – ACUTE CSR IN A 29 YEAR OLD PATIENT 
 
FIGURE 3 – CHRONIC CSR WITH SUBRETINAL PRECIPITATES 
IN A 38 YEAR OLD PATIENT 
 
 
 
 
FIGURE 4 – BULLOUS VARIANT OF CSR 
 
 
 
 
 
 
 
 
 
 
 
INVESTIGATIONS 
FUNDUS FLUORESCEIN ANGIOGRAPHY 
ACUTE CSR 
Fluorescein angiography in acute cases of classic CSC demonstrates a 
single or multifocal hyperfluorescent spots suggestive of leaks at the 
level of the RPE. Early in the angiogram, there is a focal dot-like 
hyperfluorescence representing the leakage of dye from the choroid 
through the RPE. Later, pooling of the dye occurs through the phases of 
the angiogram which respects the boundaries of the serous detachment . 
Two patterns of leakage occur.  
 The more common pattern of dye leakage, is the ink blot pattern 
which is a small dot leak increasing in size throughout the phases 
of the angiogram. 
 The classic smokestack leak described by Shimizu and Tobari in 
occurs in the minority of cases (10%), but has a dramatic 
appearance. The leakage first arises superiorly, resembling a 
smokestack, and then plumes out laterally. This pattern is thought 
to be caused by the convection currents and a protein gradient, as 
the subretinal fluid underlying the detachment has a high 
concentration of protein. Smokestack leaks causes a larger 
detachment compared to the inkblot pattern. 
In both types of leakage patterns, focal leaks are found to be more 
common nasally and in the superior half of the retina. The leakage point 
occurs in the fovea in less than 10% of cases and within the 
papillomacular bundle in 20–25% of cases. If a leakage point is not 
readily apparent on flourescein angiography, the superior extramacular 
area should be inspected carefully as gravity might cause a detachment 
below the leak. 
DIFFUSE RETINAL PIGMENT EPITHELIOPATHY 
The diffuse areas of altered RPE are readily apparent as areas of 
hyperfluorescence due to atrophy of the RPE and associated 
insignificant leaks. Capillary telangiectasis, capillary nonperfusion, and 
CNVM secondary to chronic detachments may be detected.  
FIGURE 5 – INKBLOT PATTERN OF LEAKAGE IN FFA 
 
 
 
 
FUNDUS AUTOFLOURESCENCE 
Autofluorescence photography is an investigation which is noninvasive 
and provides functional images of the fundus based on stimulated 
emission of light from lipofuscin and related molecules. Lipofuscin, 
found within the RPE, is a cellular waste product containing lipid, 
protein, and fluorophores such as A2E. The A2E precursors increase in 
number if the outer segments are not being phagocytised and they add to 
the Autofluorescence. 
Autofluorescence images can be generated by excitation of the 
fluorophores with light centered at 580 nm, detection above 695 nm 
with a barrier filter and recording by a Topcon 50μ fundus camera. 
Alternatively a Heidelberg retina angiograph (HRA) can be used which 
is based on confocal imaging. While a healthy macula has a relatively 
uniform distribution of autofluorescence, an unhealthy macula has more 
variance related to cell injury and accumulation of abnormal amount of 
fluorophores. Autofluorescence photography is important in CSR 
because it provides a noninvasive technique to study the status of both 
the RPE and outer retina and to assess atrophic changes. 
In the acute CSR eyes, the increased metabolic activity of the RPE cause 
increase in autofluorescence at the site of detachment. 
21 
In longstanding 
lesions of acute or classic CSC patients, photoreceptor cell loss leads to 
decreased or absent autofluorescence. This method therefore, provides a 
noninvasive assessment of the status of the RPE and outer retina in 
CSR. This imaging technique helps us understand the pathogenesis of 
CSR and guide us in management of individual patients. 
Autofluorescence imaging of DRPE patients varies according to the 
degree of cellular injury. There is decreased or absent autofluorescence 
within longstanding lesions due to photoreceptor cell loss. The increase 
in autofluorescence in chronic patients may be due to RPE  reactive 
changes. The descending atrophic tracts often seen in DRPE have 
characteristic patterns. Tracts of more recent origin and the outer edge 
of more chronic descending tracts exhibit hyperautofluorescence, 
reflecting the increased lipofuscin within the RPE and A2E products 
within the outer retina. Patients with a history of CSC 
that has been quiescent for many years have only hypoautofluorescent 
areas, indicative of the RPE atrophy. Autofluorescence photography, 
therefore, provides a noninvasive tool to monitor cellular function in 
CSC patients and indirectly determine visual prognosis. 
 
 
 
 
 
 
 
 
 
 
OPTICAL COHERENCE TOMOGRAPHY 
OCT provides anatomical information in all types of CSR. A Spanish 
study which was aimed at comparing OCT findings with fluorescein 
angiographic patterns documented that eyes with CSR had an optically 
empty vaulted area under the neurosensory retina consistent with 
detachment that related to fluorescein-filled areas. The patients also had 
highly small bulges protruding from the RPE which correlated to the 
leaking spots in angiography. OCT also demonstrated the presence of as 
associated PED. 
The conventional OCT is useful for detecting subclinical cystoid 
macular degeneration or foveal atrophy.54 OCT, therefore, provides a 
noninvasive imaging test complementary to fluorescein angiography. 
OCT ophthalmoscope is found to be more efficacious compared to 
conventional OCT. In a retrospective study of unilateral resolved CSR 
the involved eyes had a decrease in central foveal thickness which had a 
statistically significant correlation with visual acuity. Additional factors 
on OCT associated with poorer visual acuity were the inability to 
visualize the external limiting membrane or the boundary between 
photoreceptor bodies and outer segments. 
 
 
 
 
 
FIGURE 6 – OPTICAL COHERENCE TOMOGRAPHY IMAGE OF 
CSR 
 
 
 
 
 
 
 INDOCYANIN GREEN ANGIOGRAPHY 
Indocyanine green (ICG) angiography is used to demonstrate areas of 
choroidal vascular hyperpermeability in cases of CSR. these abnormal 
areas are localised to the inner choroid and characteristically seen in the 
mid-phases of the angiogram.  Dispersion of the dye into the deeper 
layers of the choroid is late which produces a characteristic appearance 
of larger but less prominent hyperfluorescent patches in the choroid. 
This also produces a silhouetting of the choroidal vessels. Patients with 
CSC can actually present with no fluorescein leakage during a quiescent 
phase, may have detectable areas of choroidal hyperpermeability in 
ICG. Pigment epithelial detachments can also be seen in ICG which are 
thought to be produced by choroidal hyperpermeability in areas lacking 
RPE defects which causes the leak to lift up the RPE and cause a 
pigment epithelial detachment. ICG angiography of DRPE shows 
widespread choroidal vascular hyperpermeability which is greater 
number when compared to classic CSR with larger areas of 
hyperpermeability. 
 
 
 
 
 
 
FIGURE 7 – INDOCYANIN GREEN ANGIOGRAPHY IMAGE OF 
CSR SHOWING HYPERFLUORESCENCE 
 
 
DIFFERENTIAL DIAGNOSIS 
Although the clinical and fluorescein angiographic features of CSC are 
often classic, several entities should be considered in the differential 
diagnosis: 
 CHOROIDAL NEOVASCULARISATION (CNV): This is the 
most important differential diagnosis of central serous 
chorioretinopathy. Both groups of patients are similar in that they 
may have neurosensory detachments associated with PEDs and 
areas of mottled depigmentation and/or hyperpigmentation, areas 
of RPE atrophy, and subretinal deposits of fibrin and lipid. But 
RPE thickening, notched PEDs and subretinal or subpigment 
epithelial blood are seen only in CNVM along with findings 
consistent with new vessel growth. CNVM may occur secondary 
to many different conditions and they may be differentiated by 
the other associated findings. The CNVM secondary to other 
ocular causes such as Age related macular degeneration has 
‘classic’ findings on fluorescein angiography - lacy vascular 
pattern of hyperfluorescence with increasing leakage and staining 
throughout a fluorescein angiographic evaluation. CSR reveals 
multifocal areas of choroidal vascular hyperpermeability that is 
most obvious in the mid-phases of ICG. CNVM shows a 
unilateral, unifocal area of hyperfluorescence that progressively 
increases in contrast with the surrounding choroid in the later 
phases of ICG. ICG may also aid to rule out occult CNVM.  
 TUMORS AND INFILTERATIVE CONDITIONS: leukemia, 
amelanotic melanoma, or metastatic disease, can also appear 
similar to CSR. These infiltrative lesions generally have a distinct 
appearance on comparing with the surrounding normal choroid 
associated with choroidal thickening on B scan.  
 HARADA’S DISEASE OR POSTERIOR SCLERITIS: these 
conditions may mimic CSR but have cells in the anterior chamber 
or in the vitreous with yellowish patches in the posterior pole. B 
scan shows thickening of the choroid.   
 KRONENBERGS SYNDROME: these patients have optic nerve 
pits along with a serous elevation at the macula that may be 
similar to CSR. The macular elevation due to optic nerve pits 
differs from CSR because it is generally a bilayer detachment 
caused by retinoschisis in the macula. There are no leaks in these 
patients in flourescein angiography.  
 RHEGMATOGENOUS RETINAL DETACHMENT: They may 
mimic the macular elevation in CSR, but they have a horse shoe 
tear or breaks in the periphery or in the posterior pole. 
 VASCULAR DISORDERS 
 MALIGNANT HYPERTENSION can produce a serous retinal 
detachment. The presence of systemic hypertension, Elschnig’s 
spots, shifting fluid, and choroidal or retinal vasculature changes, 
or both, can distinguish it from CSR. 
 TOXEMIA OF PREGNANCY: may present with serous retinal 
detachment. The systemic findings of hypertension, proteinuria, 
and edema will separate this condition from CSC seen in pregnant 
women. 
 DISSEMINATED INTRAVACULAR COAGULATON should 
also be considered in the differential diagnosis of serous retinal 
detachment in the appropriate clinical setting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NATURAL COURSE OF THE DISEASE AND 
OUTCOME 
Most patients with CSR resolve spontaneously with recovery of snellen 
visual acuity 
23
. The average time for the resolution of the subretinal 
fluid is three months. Most patients have a complete visual recovery 
with a best corrected visual acuity of 6/12 or better
23
. However, inspite 
of recovery of Snellen visual acuity, complaints of reduced colour 
vision, relative scotomas, micropsia, metamorphopsia, decreased 
contrast sensitivity, and nyctalopia may persist in the affected eye. Some 
patients may complain of distortion in the central field of vision inspite 
of good visual acuity. This is due to the photoreceptor damage, atrophy, 
irregular RPE pigmentation, or subretinal fibrosis. Recurrences of 
subretinal fluid and exudative detachment at the macula are common 
due to the persistent leaks or recurrents leaks and few patients may 
progress to DRPE. Recurrences can occur may occur within a few 
months or many years later. The recurrent leakage point is usually 
within 1 mm of the initial leakage point in most of the patients of 
patients. Secondary CNVM is a complication which may occur in 
patients with long standing CSR. 
 
 
 
 
 
  
TREATMENT 
The management for acute CSR followed till date by majority of 
clinicians is masterly inactivity as it has the inherent property to resolve 
spontaneously without any complications. But when there is persistence 
of the subretinal fluid for an extended period or when observation is not 
preferred due to occupational reasons or other reasons in patients 
various modalities are undertaken to hasten the resolution of the 
subretinal fluid thus reducing the central macular thickness. 
Patients may be asked to stop steroids if any history of usage is present 
and lifestyle modification may be advocated to alleviate the mental 
stress. 
The various treatment methods which are adopted are aimed at sealing 
the leak visible in fundus flourescein angiography, or to reduce the 
choroidal hyperpermeability. 
MEDICAL THERAPY 
Many drugs have been tried in the treatment of central serous 
chorioretinopathy. Because of the implication of a psychological 
component sedative and CNS suppressants were tried in the past but 
their efficacy has not been proved by randomised control trials. 
19  β 
blockers have also been suggested by certain researchers due to the 
elevated level of adrenaline in these patients. But this group of drugs 
come with its own side effects. Ketoconazole, because of its 
adrenocorticoid antagonistic property has also been studied for use in 
CSR. Though it lowered the endogenous corticosteroid levels the central 
macular thickness and visual acuity remained unchanged at 4 weeks and 
its long termed effect on these variables is not established
23 
. 
Oral Rifampicin was also used by some researchers in the treatment of 
longstanding central serous chorioretinopathy but the side effects of the 
drug may preclude its usage routinely.
24 
Mineralocorticoid antagonists like spironolactone and eplerenone have 
been studied in long standing cases, these drugs though they cause 
resolution of the subretinal fluid donot affect the central macular 
thickness or the best corrected visual acuity and require randomised 
control trials to establish the efficacy of these drugs.
24 
Epleronone has 
been shown to reduce the choroidal vasodilatation and hyperpermeabilty 
and thereby reduction in the subretinal fluid.
25 
 
Finasteride , 5α reductase inhibitor has also been recommended for use 
in central serous retinopathy
26 
but the side effects have to be kept in 
mind before prescribing it for male patients and the risk benefit ratio has 
to be established by randomised control trials. 
PHOTOCOAGULATION THERAPY 
Laser photocoagulation is the most commonly studied modality in the 
treatment of CSR. The principal goal of this treatment is to reduce the 
leakage through the RPE and cause resolution of the subretinal fluid 
with improvement in visual acuity. Laser photocoagulation to the site of 
leakage seen during flourescein angiography shortens the duration of 
macular detachment in patients with typical CSR, but does not appear to 
affect the final visual acuity. Similarly for DRPE, thermal grid laser to 
an area with small leaks appeared to cause a decrease in the amount of 
subretinal fluid present, but did not cause a long term change in the 
visual acuity. The effect of laser treatment on the rate of recurrence is 
inconclusive as it reduced the rate of recurrence in some studies, but not 
in others.
30,31
 For the severe bullous variant, laser photocoagulation did 
not confer any significant advantage in terms of temporal resolution of 
serous retinal detachment or final visual acuity outcome. Potential dire 
side effects of photocoagulation include CNV, scotoma, and RPE scar 
expansion. 
Laser photocoagulation is indicated for the following patients: 
 Symptoms greater than 4 months,  
 Leakage sites located greater than 375 mm from fixation,  
 a history of CSC in the fellow eye with an unfavorable outcome, 
 the need or desire for treatment.  
A detailed biomicroscopic examination and flourescein angiogram is 
essential to look for the development of CNVM.  
Laser photocoagulation should be performed to the leakage site with 
low-intensity energy. The laser is set for a spot size of 100–200 mm, 
power of 100–150mW, with application time of 0.1–0.2 s. With a recent 
angiogram as guidance, the more peripheral leaks are treated first.  
The amount of laser uptake is affected by several variables. These 
include 
the amount of subretinal fluid present, the degree of pigmentation of the 
RPE, which is variably pigmented in areas of chronic subretinal fluid, 
the degree of RPE detachment, and the wavelength of laser used.  
The leakage point is treated as well as a small surrounding region of 
normal RPE. Great care should be taken to obtain only a dull gray 
coagulation to avoid the possibility of secondary CNV. The patient 
should be monitored carefully to assess for recurrence or laser-induced 
complications. The subretinal fluid generally takes a few weeks to 
resorb. The visual symptoms start to improve with the reduction of the 
subretinal fluid. If hemorrhage, increased turbidity of the subretinal 
fluid, or thickening at the level of the RPE in or adjacent to the area of 
laser treatment is noted, secondary CNV should be suspected. The 
patient should have a repeat fluorescein angiogram at that point to help 
in establishing the diagnosis. Secondary CNV generally causes a 
nodular or crescent-shaped area of hyperfluorescence under or adjacent 
to the area of previous laser photocoagulation. If the original site of 
treatment was sufficiently extrafoveal, it is possible to discover and treat 
secondary CNV, in many cases, before the neovascularization extends 
under the fovea. The CNV may be treated with either thermal laser, if 
sufficient room exists, or with photodynamic therapy (PDT). 
Subthreshold micropulse diode laser has been used to treat CSR 
nowadays. These lasers can be used safely for sub foveal leaks without 
any adverse effects.  
PHOTODYNAMIC THERAPY 
This is a new treatment modality for CSR.  Studies have shown that 
PDT causes ischemia of the choriocapillaries which leads to reduced 
fluid leak and accumulation and resolution of the serous detachment. It 
may be useful for treatment of DRPE and chronic CSR where laser has 
not been effective. DRPE is a challenge to treat because of the wide 
distribution of multiple indistinct leaks. Recurrences of subretinal fluid 
do occur, but they are amenable to retreatment with PDT but pigmentary 
changes may persist. ICG angiography-guided PDT of eyes with chronic 
CSR eyes has been studied in which the location of laser light 
application, in our study, was based on regions of choroidal vascular 
hyperpermeability seen during ICG angiography that were responsible 
for the fluid leakage into the macula. Safety precautions include 
avoidance of directly treating the central fovea to help reduce the 
possibility of inducing foveal atrophy with the PDT. Full fluence and 
half fluence PDT have been found to be effective in CSR. Because of 
the high cost of PDT, its use has typically been limited in classic CSR to 
those patients with focal leaks near the centre of the fovea where laser 
photocoagulation may induce excessive harm.  
  
  
 
 
 
PART – II 
 
 
AIMS AND OBJECTIVES 
PRIMARY OBJECTIVES:  
To evaluate the efficacy of focal laser in patients diagnosed as CSR with 
extrafoveal leakage, in terms of visual acuity and central macular 
thickness and comparing it with the control group. 
SECONDARY OBJECTIVES: 
1. To study the risk factors implicated in Central serous 
Chorioretinopathy. 
2. To study the association and pattern of CSR with the use of 
steroids (Systemic, Inhalers, Ointment etc.) 
3. To study the FFA patterns and site of extrafoveal leakage in Central 
Serous chorioretinopathy. 
4. To study the use of OCT in Central Serous Chorioretinopathy 
 
 
 
 
 
MATERIALS AND METHODS 
SUBJECT SELECTION 
60 patients with Central Serous Chorioretinopathy attending Uvea and 
Retina services of Regional Institute of Ophthalmology and Government 
Ophthalmic Hospital were included in the study. 
INCLUSION CRITERIA 
Patients with CSR in whom 
1. Presence of Sub Retinal Fluid involving the fovea for a period of 3 
months or longer in optical coherence tomography (OCT) images 
2. Patients with CSR induced leakage 500μm away from fovea as 
demonstrated in FFA. 
3. Patients with a history of CSR in the other eye with an unfavourable 
outcome. 
4. Patients with CSR with visual acuity 6/12 ( logMAR 0.3) or worse  
EXCLUSION CRITERIA 
1. Patients with serous retinal detachment unrelated to CSR. 
2. Eyes with history of previous Photodynamic therapy or laser 
photocoagulation. 
3. Patients with ocular infective and inflammatory diseases. 
METHODS: 
All patients diagnosed who were diagnosed as CSR underwent thorough 
history taking to assess the presence of risk factors causing CSR.  
Then patients underwent the following investigations 
Visual acuity 
Automated refractometry reading and Subjective best corrected visual 
acuity 
Amslers Grid 
Slit lamp examination 
Slit lamp biomicroscopy with 90D 
Indirect ophthalmoscopy 
Fundus fluorescein angiography 
Optical coherence tomography 
60 patients who satisfied the inclusion criteria were selected and 
randomly assigned to laser group and study group. The patients in the 
laser group underwent focal laser wherein pinpoint leaks were treated 
with burns of spot size 100 µm, power of 100 mW of 100 ms duration. 
The leaks were treated with 3 confluent burns. 
 
 
FOLLOW UP 
Patients were reviewed at 4 weeks and 12 weeks post laser. Visual 
acuity was reassessed. Slit lamp examination and dilated fundus 
examination with 90D and Indirect ophthalmoscopy was done. Optical 
coherence tomography was again repeated during the two visits to 
reassess the central macular thickness. 
 
DATA ANALYSIS AND RESULTS 
Following analysis was done 
 The visual outcome by measuring best corrected visual acuity. 
 Assessment of Central Macular thickness and resolution of 
Subretinal fluid by Optical coherence tomography. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
1. AGE DISTRIBUTION:  
TABLE-1 
AGE(in years) NO OF PATIENTS PERCENTAGE 
21-30  7 11.6 
31-40 33 55 
41-50 15 25 
>50 5 8.3 
TOTAL 60 100 
 
FIGURE - 1 
Our study population included patients from 24 – 59 years with a mean 
age of 38.7. Majority of the patients (55%) belonged to the age group of 
31 – 40 years and 25% of patients belonged to the 41 – 50 years group. 
Only 11.6% belonged to 21 – 30 years age group and 8.3% were above 
the age group of 50 years.  
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2. GENDER DISTRIBUTION: 
TABLE2: 
SEX NO OF PATIENTS PERCENTAGE 
MALE 44 73.3 
FEMALE 16 26.6 
TOTAL 60 100 
       
FIGURE -2  
 
 
 
In our study,male subjects outnumbered females subjects.  73.3% of the 
study population were males and  26.6% were females. 
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3.LATERALITY 
TABLE 3: 
LATERALITY NO OF PATIENTS PERCENTAGE 
UNILATERAL 50 83.3 
BILATERAL 10 16.6 
TOTAL 60 100 
      
FIGURE – 3 
 
 
In our study 83.3.% of the patients had unilateral disease and bilateral 
CSR was present in 16.6% of the patients. In patients with unilateral 
disease 27 patients had involvement of the right eye and in 23 patients 
left eye was involved.  
 
50
10
NO OF PATIENTS
UNILATERAL
BILATERAL
4. BEST CORRECTED VISUAL ACUITY 
TABLE 4: 
BCVA (logMAR) NO OF PATIENTS PERCENTAGE 
6/6 - 6/12 (0 – 0.3) 3 5 
6/18 – 6/24 (0.5 – 0.6) 40 66.7 
6/36 – 6/60 ( 0.8 – 1) 17 26.7 
TOTAL 60 100 
          
FIGURE – 4 
 
 
 
At presentation, 66.7% of patients had a BCVA of 6/18 -6/24, and 26.7% 
of patients had a BCVA between 6/36 and 6/60. 5% of the patients 
presented with a BCVA of 6/6 – 6/9. 
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5. RISK FACTORS 
    TABLE 5 
RISK FACTOR NO OF 
PATIENTS 
PERCENTAGE 
RECENT MENTAL STRESS 23 38.3 
TYPE A PERSONALITY 17 28.3 
SMOKING  16 26.7 
SLEEP DISTURBANCE 13 21.7 
ALCOHOLISM 9 15 
STEROID USAGE 8 13.3 
HYPERTENSION 7 11.7 
DIABETES 5 8.3 
 
                        FIGURE – 5 
 
 
Presence of mental stress in the recent past due to personal issues was 
found to be the most significant risk factor with 38.3% of patients 
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confiding to have the history. The next significant risk factor type A 
personality with 28.3% of patients belonging to this category. Smoking 
was present in 26.7% of the patients and sleep disturbances in 21.7% of 
the patients. 13.3% of patients included in our study gave history of 
steroid usage. Alcoholism, diabetes and hypertension were present in 
15%, 8.3% and 11.7% of the patients respectively. Many patients had a 
combination of one or more risk factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. ASSOCIATION WITH STEROID USAGE  
      TABLE - 6 
HISTORY OF 
STEROID 
USE 
ROUTE NO OF 
PATIENTS 
PERCENTAGE 
 
  PRESENT 
ORAL 6     
    13.3% TOPICAL 1 
NASAL 
SPRAY 
1 
ABSENT  52 86.7% 
TOTAL  60 100 
FIGURE – 6 
 
Among patients with a history of steroid usage, 6 patients gave history 
of using oral steroids for systemic illness. One patient had a history of 
using steroid nasal spray for allergic rhinitis and one patient gave history 
of prolonged use of topical steroid following cataract surgery.  
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7. PRESENTING  COMPLAINTS  
    TABLE- 7       
COMPLAINTS NO OF PATIENTS PERCENTAGE 
CENTRAL 
SCOTOMA 
44 73.3% 
METAMORPHOPSIA 16 26.7% 
TOTAL 60 100 
 
      FIGURE - 7 
        
 
In our study group, 44% of patients gave history of a central scotoma 
while only 16% of patients were able to give a history of 
metamorphopsia. along with complaints of defective vision. 
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8. RECURRENCE OF CSR 
          TABLE 8 
RECURRENCE EYE NO OF 
PATIENTS 
    YES SAME EYE 7 
OTHER EYE 10 
NO  43 
TOTAL  60 
 
      FIGURE -8 
 
 
Among our 60 study subjects, 17 patients gave a previous episode of 
CSR among whom 7 patients had an episode in the same eye wheres as 
10 patients had an previous history in the other eye. Remaining 43 
patients had a persistent CSR lasting for more than 3 months. 
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9.FUNDUS FLUORESCEIN ANGIOGRAPHIC 
PATTERNS 
      TABLE 9 
FFA  PATTERN  NO OF PATIENTS PERCENTAGE 
INK BLOT  39 65 
SMOKE STACK 21 35 
RPE CHANGES 17 28.3 
PED 15 25 
FIGURE 9 
 
The commonest pattern in fluorescein angiography was the ink blot 
pattern, 65% while the remaining 35% of the patients had a smock stack 
pattern. The CSR was associated with PED in 25% of the patients. 
Retinal pigment epithelial changes and defects were seen in 28.3% of 
the patients. One patient had congenital hypertrophy of the retinal 
pigment epithelium (bear track appearance) associated with CSR. 
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FUNDUS FLUORESCEIN ANGIOGRAPHY OF RIGHT 
EYE 50 YEAR OLD PATIENT SHOWING INK BLOT 
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FUNDUS FLUORESCEIN ANGIOGRAPHY OF 39 YEAR 
OLD PATIENT SHOWING SMOKE STACK PATTERN 
OF LEAKAGE 
 
 
 
 FUNDUS FLUORESCEIN ANGIOGRAPHY OF 39 YEAR 
OLD PATIENT SHOWING SMOKE STACK PATTERN 
OF LEAKAGE 
 
 
 
 
 
10.SITE OF LEAKAGE IN ANGIOGRAPHY 
TABLE 10 
SITE NO OF PATIENTS PERCENTAGE 
STQ 12 20 
ITQ 15 25 
SNQ 24 40 
INQ 9 15 
TOTAL 60 100 
 
FIGURE 10 
 
In our patients 40% of the patients had leakage in the superonasal 
quadrant, 25% of patients had leakage in the infero temporal quadrant. 
20% of patients had leak in the superotemporal quadrant and 15% of 
patients had leak from the inferonasal quadrant. Patients with leakage in 
the foveal avascular zone were excluded from the study.  
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11. OPTICAL COHERENCE TOMOGRAPHY 
The mean central macular thickness of the control group at presentation 
was 414.6± 83.5µm and that of the laser group was 422.3±92.4µm. 
Pigment Epithelial Detachment was present in 40% of patients which 
corresponded with that of fundus fluorescein angiography. 
 
      FIGURE - 11 
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12. ANALYSIS OF EFFICACY OF FOCAL LASER 
60 EYES OF 60 patients who were diagnosed as CSR by fundus 
flourescein angiography and OCT satisfying aforementioned criteria 
included in the study. The patients were assigned into two groups of 30 
patients each by simple randomization.  
 Group 1 was the observational group where the patients were 
observed over a period of 3 months. This served as the control 
group for our study.  
 The patients in group 2 were the patients selected to undergo focal 
laser and served as the study group. These patients underwent 
focal laser wherein pinpoint leaks were treated with burns of spot 
size 100 µm, power of 100 mW of 100ms duration. The leaks 
were treated with 3 confluent burns. The visual acuity of the 
patients was recorded at 4 weeks and 12 weeks post laser. They 
also underwent OCT to look for the central macular thickness and 
resolution of subretinal fluid at 4 weeks and 12 weeks. 
BASELINE PARAMETERS 
 The mean central macular thickness of the control group at 
presentation was 414.6± 83.5µm and that of the laser group 
was 422.3±92.4µm.  
 The mean visual acuity of the control group at presentation 
was 0.64 ±0.2 and that of the laser group was 0.6±0.15 at 
presentation (in logMAR).  
 The control group was age and sex matched to the study group 
and was comparable to the study group in terms of visual 
acuity (p = 0.736) and central macular thickness (p= 0.188) 
with no statistical difference between the two groups by 
independent t test at presentation. 
TABLE 12  
BASELINE 
Group N Mean Std. Deviation Std. Error 
Mean 
P value 
CMT 
Control 30 414.6000 83.46736 15.23899 
0.736 
Laser 30 422.3000 92.36179 16.86288 
Vision 
Control 30 .6400 .17734 .03238 
0.188 
Laser 30 .5833 .15105 .02758 
         FIGURE - 12 
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The patients of the laser group were evaluated four months 
after the focal laser to the leakage points and the patients of the 
control group were evaluated after four months after their first 
presentation. 
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        TABLE 13 
4 weeks Group N Mean 
Std. 
Deviation 
Std. Error 
Mean 
p value 
CMT 
Control 30 309.8333 47.71473 8.71148 
0.001 
Laser 30 257.9667 63.61061 11.61365 
Vision 
Control 30 .4333 .21227 .03875 
0.000 
Laser 30 .2000 .15757 .02877 
 
 The Central macular thickness of the control group at 
four weeks was 309.8±47.7 µm and that of the laser 
group was 257.9 ±63.6µm.  
 There was a 25.3% decrease in the central macular 
thickness of the control group and and 38.3% decrease in 
the study group.  
 The difference between the 2 groups at 4 weeks in terms 
of visual acuity (p<0.01) and CMT (p<0.05) was 
statistically significant. Though the difference between 
the baseline CMT and CMT at four weeks was significant 
for both groups (p<0.01) by paired T test, the percentage 
of decrease was more in the laser group when compared 
to the control group. 
 
 
 
FIGURE 14 
 
 
 The visual acuity of the control group at four weeks had a 
mean 0.43± 0.2 and the control group was 0.2±0.1. The 
difference in visual acuity between the baseline and at 
four weeks of the laser group was statistically significant 
by paired t test (p<0.05) whereas it was not statistically 
significant in the control group(p= 0.136) 
FIGURE 15 
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   TABLE 14  
12 WEEKS Group N Mean Std. Deviation 
Std. Error 
Mean 
p value 
CMT 
Control 30 260.5667 38.07043 6.95068 
0.000 
Laser 30 215.1000 22.08190 4.03159 
Vision 
Control 30 .2167 .17436 .03183  
0.001 
Laser 30 .0833 .11472 .02095 
 
 The mean central macular thickness of the study group 
was 260.6± 38 µm and that of the laser group was 215.1± 
22 µm.  
 The difference in the central macular thickness between 
the two groups was statistically significant (p<0.01) 
 There was a 37.3% decrease in central macular thickness 
at 12 weeks from the baseline in the control group. This 
was statistically significant (p<0.01) by paired t test. The 
decrease in CMT of the laser group at 12 weeks was a 49% 
which was statistically significant (p <0.01). 
                 FIGURE 16 
 The mean visual acuity of the control group was 0.21 ± 
0.2 in logMAR whereas that of the study group was 0.1 
±0.2. The difference in visual acuity between both the 
groups was statistically (p<0.05). The improvement in 
visual acuity of both the laser group and the control group 
was statistically significant by paired t test (p<0.01).   
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FIGURE 19- COMPARISON OF BCVA OF LASER AND 
CONTROL GROUPS AT PRESENTATION AND AT 4 AND 12 
WEEKS 
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EFFECT SIZE ANALYSIS 
Since the difference between the laser groups and control groups in 
terms of visual acuity and Central Macular Thickness is significant by 
paired t test, the effect size analysis is done to assess the usefulness of 
the intervention. 
       TABLE 15 
GROUP           CMT         BCVA 
COHEN d r COHEN d r 
CONTROL 
GROUP 
2.37 0.76 2.52 0.78 
LASER 
GROUP 
3.08 0.84 3.80 0.88 
   As depicted in the table the effect between baseline and the 12 months 
for CMT is 0.76 for the control group however the effect for the study 
group is 0.84. Similarly the r= 0.78 for the control group whereas it is 
0.88 for the laser group. This shows that the focal laser has a 
significant effect in the reduction of the central macular thickness 
and improvement in visual acuity when compared with the control 
group.  
 
 
 
 
 
 
 
 
FIGURE 20 – 28 YEAR OLD PATIENT FROM STUDY GROUP 
SHOWING RESOLUTION OF THE DETACHMENT  
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DISCUSSION 
This study was conducted in the Uvea and Retina services of Regional 
Institute of Ophthalmology, Government Ophthalmic Hospital wherein 
60 eyes of 60 patients diagnosed as CSR were included in the study. 
1. AGE 
The mean age in our study was found to be 38.7 years. The study 
conducted by Spaide et al and Tittl et al found the mean age to be 51 
years in individuals with Central serous Chorioretinopathy
9,10
. The mean 
age in our study is lesser than these previous studies. This may be 
because of the increasing incidence of stress and other risk factors like 
hypertension and smoking in younger individuals. 
2. SEX DISTRIBUTION 
The male to female ratio in our study was found to be 2.75:1 with a 
male preponderance. The previous studies conducted also show a male 
preponderance up to a ratio of 6:1.
9,10
 The increased incidence in male 
may be due to the increased prevalence of risk factors among males. 
3. LATERALITY 
Only 16.6% of the patients had bilateral CSR in our study group. 
Among the 10, patients 4 patients (40%) of patients have history of 
systemic steroid usage. Study conducted by EA Bouzas et al found 
steroids to cause bilateral, atypical CSR in patients and thus steroids 
should not be used in the treatment of CSR. 
4. RISK FACTORS 
Recent history of mental stress was found to be the commonest risk 
factors with 38.3% of the patients having the history. The next highest 
risk factor was type A personality with 28.3% of the patients having this 
risk factor. Smoking was found in 26.7% of the patients compared to 
alcoholism which was found in 15% of the patients. 11.7% of the 
patients had hypertension and 8.5% of the patient had diabetes. History 
of steroid usage was found in 13.3% of the patients. This correlates to 
many risk factors cited by Haimovici et al. 
16
 there were no pregnant 
females in our study.  
5. ASSOCIATON WITH STEROID USAGE 
Among the 60 patients, only 13.3% of the patients had history of steroid 
usage. But in patients with bilateral CSR 50% of patients gave history of 
systemic steroid usage. Among them one patient who was on topical 
steroid had unilateral CSR. Therefore systemic steroid usage is a 
significant risk factor for bilateral CSR and in patients with bilateral 
condition this history should be asked for and patients should be asked 
to stop steroid and be put on other steroid sparing agents as per the 
requirements of the disease condition.
19
  
Study conducted by EA Bouzas et al found steroids to cause bilateral, 
atypical CSR in patients and thus steroids should not be used in the 
treatment of CSR. 
6. PRESENTING COMPLAINTS 
73% of the patients complained of a central scotoma on presentation 
while 27% of the patients were able to appreciate metamorphopsia along 
with complaints of defective vision. 
 7.RECURRENCE OF CSR 
Among our study population, 28.3 % of patients had previous history of 
CSR suggesting recurrence. 7 patients had an episode in the same eye 
wheres as 10 patients had an episode in the other eye. This corresponds 
to the Wilmer Retinal Vascular Centres study of CSR which documented 
a recurrence rate between 30% - 33%.
31 
8. FUNDUS FLUORESCEIN ANGIOGRAPHIC 
PATTERNS 
The ink blot pattern was present in 65% of our patient with the smock 
stack pattern being present in only 35% of the patients. 25% patients had 
an associated pigment epithelial detachment with retinal pigment 
epithelial changes being present in 28.3% of the patients. The leaks were 
found to be more common in the superonasal quadrant in our study, with 
40% of patients having leakage at this site. Patients with foveal leakage 
were excluded from our study. 
The study conducted by Shahin MM showed 35% of patients had 
multifocal leaks. The commonest site of leak was the macula in 79% of 
patients. Extrafoveal leakage was seen in 14% of patients and 
peripapillary leakage was seen in 12% of patients. The inkblot pattern 
was found in 53% of patient with RPE atrophic changes in 84% of the 
patients.
28 
9. OPTICAL COHERENCE TOMOGRAPHIC 
ASSESSMENT
 
The mean central macular thickness of the control group at presentation 
was 414.6± 83.5µm and that of the laser group was 
422.3±92.4µm.Pigment Epithelial Detachment was present in 40% of 
patients which corresponded with that of fundus fluorescein angiography.
 
There was no evidence of Choroidal Neovascularisation Membrane in 
any patients at the time of presentation. 
Two distinct pattern of OCT findings have been documented in previous 
studies.
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 An optically empty elevated area of variable dimensions can 
be seen which corresponds to fundus flourescein angiography. Highly 
characteristic small bulges could be observed protruding from the retinal 
pigment epithelium corresponding to the leaking spots in fundus 
flourescein angiography. In the other variant, semicircular spaces 
beneath under the RPE with retinal thinning can be seen. 
10.ANALYSIS OF THE EFFICACY OF FOCAL LASERS 
In our study we documented a significant decrease in the central 
macular thickness at 4 weeks and 12 weeks post laser where the central 
macular thickness reduced by 38.3% at four weeks and 49% at 12 weeks 
which was statistically significant (p<0.001) when compared with the 
control group. In the control group the central macular thickness 
reduced only by  25.3% at 4 weeks and 37.3% at 12 weeks. There was 
also a significant improvement in the visual acuity at 4 weeks and 12 
weeks in the laser group which was statistically significant when 
compared with the control group (p<0.01). No side effects of laser were 
documented in our study subjects during the study period.. Therefore 
this shows that laser treatment reduces the duration of the CSR along 
with a significant improvement in
 
visual acuity. In a study conducted by 
Robertson et al, showed that direct laser photocoagulation reduced the 
central macular thickness and significantly reduced the duration of CSR 
when compared to patients undergoing sham laser and reduces the 
recurrences of CSR.
30 
while the study conducted by Ficker and 
colleagues showed that Argon laser does not reduce the recurrences of 
CSR which may develop due to leakage in sites other than the 
previously lasered site in the retina.
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CONCLUSION 
1. Focal lasers are effective in cases of central serous 
chorioretinopathy which persists for a period of more than three 
months. Focal lasers can be used effectively to shorten the 
duration of the disease and results in the resolution of the 
subretinal fluid and improvement in visual acuity significantly by 
4 weeks. 
2. Mental stress, type A personality and sleep disorders are found to 
be significant risk factors in patients with CSR in our study. 
3. Systemic steroid usage is found to be a significant risk factor in 
patients with bilateral CSR. 
4. The most common site of extrafoveal leakage in fundus 
flourescein angiography in our study was found to be in the 
superonasal quadrant. (40%). 
5. The ink blot pattern was found to be most common pattern in 
fundus flourescein angiography (present in 65% of the patient). 
6. CSR was found to be associated with Retinal Pigment Epithelial 
detachment in 25% of the patients by FFA and OCT 
 
 
 
 
FUTURE PROSPECTS 
1. To study the long term effects of lasers in patients who underwent 
focal lasers in terms of side effects like Scotoma and Choroidal 
neovascularization. 
2. To assess the frequency of recurrence of CSR in patients who 
underwent lasers when compared with a control group. 
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             PROFORMA 
Name :        Age :            Sex: 
OP NO: 
Address and phone number: 
 
Occupation:  
Night shifts:yes/no 
Complaints:defectivevision/scotoma/metamorphopsia/microps
ia/headache/ others 
History: past eye illness/ similar episode/ duration of 
recurrence 
Personal history: Mental stress/ Allergy/ Smoking/ Drug 
intake/ History of steroid intake/ 
Systemic illness/ h/s/o type A Personality 
Medical/Surgical History:  
 
EXAMINATION OF EYE:  
Visual Acuity RE LE 
Tension   
Fields   
AR/Subjective   
Slit Lamp 
Examination 
  
Fundus 
Examination 
Direct 
Ophthalmoscopy 
90D 
IDO 
  
Amslers Grid   
Fundus Flouresce in 
Angiography 
Pattern 
Site of Leak 
FAZ 
Others 
  
Optical Coherence 
Tomography 
Central Macular 
thickness 
Subretinal Fluid 
PED- yes/no 
  
 
 
 
 
GENERAL EXAMINATION : CVS 
          RS 
CNS 
P/A 
INVESTIGATIONS: 
TREATMENT: Laser / placebo group 
Spot Size  
Number of burns  
Duration  
Power  
Follow UP 
Visual acuity 4 WEEKS 12 WEEKS 
AR/ Subjective   
Tension   
Amslers Grid   
Central Foveal 
Thickness 
  
Sub retinal fluid   
 
KEY TO MASTERCHART 
 
BCVA      - Best Corrected Visual Acuity 
 
RISK FACTORS 
N.S. / S.D.     - Night Shift/ Sleep Disturbance                          
ALC/ SMOKER    - Alcoholic/ Smoker 
DM/ HTN     - Diabetes Mellitus/ Hypertension 
T.A.P      - Type A Personality 
M.S.      - Mental stress 
 
S.U.      - Steroid Usage 
 
AMSLERS GRID 
C.S.      - Central Scotoma 
MM      - Metamorphopsia 
 
PREVIOUS ATTACK 
S.E.      - Same Eye 
O.E.      - Other Eye 
 
FFA      - Fundus Fluorescein Angiography 
D.C.F.      - Delayed Choroidal Filling 
I.B.P.      - Ink Blot Pattern  
S.S.P      - Smoke Stack Pattern 
RPE C      - Retinal Pigment Epithelial Changes 
PED      - Pigment Epithelial Detachment 
 
SITE OF LEAK 
STQ      - Superotemporal Quadrant 
ITQ      - Inferotemporal Quadrant 
SNQ      - Superonasal Quadrant 
INQ      - Inferonasal Quadrant 
 
OCT      - Optical Coherence Tomography 
CMT      - Central Macular Thickness 
CNVM     - Choroidal Neovascular Membrane 
 
S.G.      - Study Group 
1      - Control Group 
2      - Laser Group 
 
 
 
 
 
